Rubin Lab

Publications

Found 184 results
Filters: First Letter Of Last Name is R  [Clear All Filters]
2005
Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al..  2005.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.. Cancer Cell. 8(5):393-406.
Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al..  2005.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.. Cancer Cell. 8(5):393-406.
Kim R, Demichelis F, Tang J, Riva A, Shen R, Gibbs DF, Mahavishno V, Chinnaiyan AM, Rubin MA.  2005.  Internet-based Profiler system as integrative framework to support translational research.. BMC Bioinformatics. 6:304.
Kim R, Demichelis F, Tang J, Riva A, Shen R, Gibbs DF, Mahavishno V, Chinnaiyan AM, Rubin MA.  2005.  Internet-based Profiler system as integrative framework to support translational research.. BMC Bioinformatics. 6:304.
Dhanasekaran SMohan, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA, Chinnaiyan AM.  2005.  Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty.. FASEB J. 19(2):243-5.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R et al..  2005.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.. Science. 310(5748):644-8.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R et al..  2005.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.. Science. 310(5748):644-8.
2006
Rubin MA, Chinnaiyan AM.  2006.  Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.. Lab Invest. 86(11):1099-102.
Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R et al..  2006.  Defining aggressive prostate cancer using a 12-gene model.. Neoplasia. 8(1):59-68.
Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R et al..  2006.  Defining aggressive prostate cancer using a 12-gene model.. Neoplasia. 8(1):59-68.
Demichelis F, Magni P, Piergiorgi P, Rubin MA, Bellazzi R.  2006.  A hierarchical Naïve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays.. BMC Bioinformatics. 7:514.
Andrén O, Fall K, Franzén L, Andersson S-O, Johansson J-E, Rubin MA.  2006.  How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 175(4):1337-40.
Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA.  2006.  Prognostic factors in lymph node-positive prostate cancer.. Urology. 67(5):1016-21.
Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-M, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG et al..  2006.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.. Cancer Res. 66(17):8337-41.
2007
Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener P-A, Moch H, Rubin MA.  2007.  Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer.. Hum Pathol. 38(10):1454-62.
Setlur SR, Royce TE, Sboner A, Mosquera J-M, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA.  2007.  Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.. Cancer Res. 67(21):10296-303.
Setlur SR, Royce TE, Sboner A, Mosquera J-M, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA.  2007.  Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.. Cancer Res. 67(21):10296-303.
Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R et al..  2007.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.. Neoplasia. 9(3):200-6.
Mosquera J-M, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA et al..  2007.  Morphological features of TMPRSS2-ERG gene fusion prostate cancer.. J Pathol. 212(1):91-101.
Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA.  2007.  A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.. Arch Pathol Lab Med. 131(7):1103-9.
Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA.  2007.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.. Hum Pathol. 38(5):696-701.
Barry M, Perner S, Demichelis F, Rubin MA.  2007.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.. Urology. 70(4):630-3.
Perner S, Mosquera J-M, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM et al..  2007.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.. Am J Surg Pathol. 31(6):882-8.
Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera J-M, Pawitan Y, Lee C et al..  2007.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.. Oncogene. 26(31):4596-9.
Demichelis F, Rubin MA.  2007.  TMPRSS2-ETS fusion prostate cancer: biological and clinical implications.. J Clin Pathol. 60(11):1185-6.